Skip to main content

Table 4 OCT -derived study endpoints

From: Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography

 

Standard of care

(N = 31)

Alirocumab

(N = 30)

P Value

Minimum fibrous cap thickness, um

 Baseline

116.4 (90.1 to 136.2)

126.0 (87.5 to 145.5)

0.44

 After 36 weeks treatment

124.2 (98.2 to 144.3)

144.0 (111.5 to 151.8)

0.049

 Changes from baseline

13.2 (7.4 to 18.6)

18.0 (10.8 to 29.2)

0.029

Maximum lipid arc, degree

 Baseline

110.9 (90.2 to 132.4)

109.6 (89.8 to 130.0)

0.53

 After 36 weeks treatment

102.2 (87.0 to 123.1)

93.5 (77.5 to 108.1)

0.19

 Changes from baseline

−8.4 (−2.0 to −10.5)

−15.1 (−7.8 to − 24.5)

0.008

Minimum lumen area, mm2

 Baseline

2.47 (2.20 to 2.74)

2.32 (2.07 to 2.63)

0.22

 After 36 weeks treatment

2.60 (2.19 to 2.90)

2.57 (2.27 to 2.90)

0.77

 Changes from baseline

0.13 (0.12 to 0.24)

0.20 (0.10 to 0.33)

0.006

TCFA, %(n)

 Baseline

25.8 (8)

20.0 (6)

0.59

 After 36 weeks treatment

16.1 (5)

3.3 (1)

0.09

  1. TCFA thin-cap fibroatheroma